This issue of Surgical Clinics of North America, guest edited by Drs. Jeffrey M. Farma and Andrea Porpiglia, is devoted to Sarcoma. They have assembled expert authors to review the following topics: Epidemiology and Etiology of Sarcomas; Management of Extremity Sarcomas; Management of Retroperitoneal Sarcomas; Management of Dermatofibrosarcoma Protuberans; Management of Desmoids; Management of Truncal Sarcomas; Management of Bone Sarcomas; Management of Pediatric Sarcomas; Local Recurrence of Sarcomas; Management of Metastatic Disease; Imaging of Sarcomas; Management of Gastrointestinal Stromal Tumors; Management of Breast Sarcoma; Chemotherapy for Sarcomas; Pathology and Classification of Sarcomas; Radiation Therapy for Sarcomas; and more!

This volume will describe recent progress and future directions in radiation oncology and biology research, focusing on strategies designed to improve disease control and reduce the risk of long-term adverse effects on patients. As more and more patients are becoming long-term survivors, this strategy will become increasingly important--in radiation oncology and throughout the field of oncology.

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Chandrajit P. Raut, is devoted to Sarcomas. Dr. Raut has assembled expert authors to review the following topics: Sarcoma: Histologic Subtypes and Changes in the Recent WHO Classification; Distinguishing Radiologic Characteristics of Sarcoma Histologic Subtypes; Extremity Soft Tissue Sarcoma: Tailoring Resection to Histologic Subtype; Retroperitoneal Sarcoma: Fact, Opinion, and Controversy; Breast Sarcoma; Management of Sarcoma Metastases to the Lung; Gastrointestinal Stromal Tumor; Liposarcoma: Surgical Management and Future Targeted Therapy; Myxofibrosarcoma; Malignant Peripheral Nerve Sheath Tumor; Desmoid Fibromatosis: Evolving Treatment Standards; Dermatofibrosarcoma Protuberans: Surgery v. Mohs; Radiation Therapy: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, IORT, and Brachytherapy; Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?; and more!

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.

This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.

This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.

This issue of Surgical Clinics of North America, guest edited by Dr. Jeffrey M. Hardacre, is devoted to Pancreatic Cancer and Periampullary Neoplasms. He has assembled expert authors to review the following topics: Genetics of Pancreatic Cancer and its Implication on Therapy; Familial Pancreatic Cancer and Screening of High-risk Individuals; Imaging Evaluation of Pancreatic Cancer; Endoscopic Evaluation in the Work-up of Pancreatic Cancer; Definition and Management of Borderline Resectable Pancreatic Cancer; Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer Surgery; Surgical Therapy for Pancreatic and Periampullary Cancer; Post-Pancreatectomy Complications and Management; Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer; Management of Locally Advanced Pancreatic Cancer; Management of Metastatic Pancreatic Cancer; Management of Pancreatic Neuroendocrine Tumors; Management of Intraductal Papillary Mucinous Neoplasms; Palliative Care and Surgery in Pancreatic Cancer; Enhanced Recovery Pathways in Pancreatic Cancer; and more!

The book conveys a comprehensive knowledge of long and short ncRNAs in cancer regulation and their potentials as diagnostic biomarkers and therapeutic targets. Topics covered include the molecular mechanisms of various classes of ncRNAs (with emphasis on long non-coding RNAs and microRNAs) in cancer, the functional roles of ncRNAs in regulating different cancer hallmarks (including proliferation, apoptosis, stem-cell properties, epithelial-mesenchymal transition, metabolism, angiogenesis, tumor-host interactions and therapeutic resistance), the role of ncRNAs in regulating cancer signaling circuitry programs (highlighting their involvement in c-myc, p53 and NFkB signaling), a systemic summary of clinical and preclinical studies that evaluate the potential of ncRNA signatures for cancer diagnosis and prognosis and strategies to delivery short ncRNAs as therapeutic molecules for cancer treatment. This book may serve as a comprehensive resource for researchers, graduate students and oncologists in ncRNA and cancer research and help drug development by identifying ncRNA targets.

This issue of Neuroimaging Clinics of North America focuses on Adult Brain Tumors, and is edited by Dr. Lara Brandao. Articles will include: Posterior Fossa Tumors in Adult Patients; Lymphomas and Adult Brain Tumors; Pre-Treatment Evaluation of Gliomas; Post Treatment Evaluation of Gliomas; Metastasis in Adult Brain Tumors; Extraparenchymal Lesions in Adult Brain Tumors; Interesting Case Studies in Adult Brain Tumors; Advanced MR Imaging Techniques in Daily Practice; and more!

Each chapter will focus on the known molecular characteristics of specific childhood cancers, focusing on how the molecular 'drivers' can be exploited from a therapeutic standpoint with currently available targeted agents. Where applicable, integration of targeted therapies with conventional cytotoxic agents will be considered. This volume will provide a comprehensive summary of molecular characteristics of childhood cancers, and how the changes involved in transformation provide us with opportunities for developing relatively less toxic, but curative, therapies.

This book presents the theoretical foundations of Systems Biology, as well as its application in studies on human hosts, pathogens and associated diseases. This book presents several chapters written by renowned experts in the field. Some topics discussed in depth in this book include: computational modeling of multiresistant bacteria, systems biology of cancer, systems immunology, networks in systems biology.

After nearly three decades of providing medical care for women and men facing breast cancer, surgeon S. David Nathanson calls the survival rates today an ordinary miracle. Ordinary because the vast majority of patients now do live at least 20 years after diagnosis due to enormous progress that has been made in medicine; and a miracle too because of the intangible qualities such as faith and hope that seem key to success in battling the disease. In this book, survivors describe their experiences, emotions, and means to overcome the disease. S. David Nathanson is an esteemed, longtime surgeon who calls the survival rates today for women and men facing breast cancer nothing short of an ordinary miracle. Ordinary because the vast majority of patients live at least two decades after diagnosis, due to great advances that have been made in early detection, surgery, radiation, and chemotherapy. But also a miracle because we know that key elements for a woman or man succeeding in a personal battle against breast cancer include completely intangible qualities of courage, fortitude, trust, persistence, faith, and hope. Although science cannot completely explain it, a supportive network of family and friends with those qualities also empower patient survival and recovery. In these pages, Nathanson shares stories from his patients, teaching us about the experience of breast cancer and explaining how they found and fueled the will and power to defeat the disease. Even surgeon Nathanson himself cannot fully describe what goes through the hearts and minds of breast cancer patients as they discover, deal with, and finally triumph over the diagnosis. So in this book he acts as a narrator, letting his ordinary yet miraculous cancer survivors tell their stories, certainly filled with fear of the known and unknown, and with pain, but opening up to courage, love, sometimes humor, and finally hope. It is hope that firms up their resilience; hope that initiates their fortitude. Hope is an important component of healing, says the surgeon. Seventy-one survivors, including one man, tell their stories to ilustrate every step of the experience.

This issue of the Surgical Pathology Clinics entitled "Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Tumors" is being edited by Dr. Lynette Sholl and will cover molecular pathology in a wide array of anatomic locations including, salivary gland, lung, bladder, glioma, endometrium, colon, pancreaticobiliary tract, sarcoma, myeloid neoplasams, and lymphomas.

Gynecologic malignancies, especially endometrial and ovarian cancers are among the most important and most severely affected by obesity. This volume of Energy Balance and Cancer, written by the world's leading experts in this field, is arranged to provide a transdisciplinary assessment of the pertinent issues, results of relevant research on mechanisms, and control, strategies for dealing with affected patients and improving outcomes and future research needs. The volume comprehensively covers the epidemiology linking obesity to endometrial and ovarian cancer as well as the public awareness of this critical problem. Subsequent chapters explain biologic aspects of linkages between energy balance and gynecologic malignancies. The volume further outlines strategies to disrupt the linkage between obesity and gynecologic malignancies and concludes with a series of chapters focused on management strategies for obese patients with gynecologic malignancies. This volume provides a valuable resource for all physicians, scientists and other transdisciplinary investigators and practitioners interested and involved in energy balance and cancer. It should be a particularly useful guide to optimize outcomes for all practitioners dealing with patients with gynecologic malignancies challenged by energy balance issues. Moreover, it should serve as a useful guide to students and investigators interested in conducting further research on defining and disrupting the important linkage between energy balance and gynecologic malignancies.

This issue of Radiologic Clinics of North America focuses on Extranodal Lymphoma from Head to Toe, and is edited by Dr. Mark Murphey. Articles will include: Pathology of Extranodal Lymphoma; Pulmonary and Mediastinal Extranodal Lymphoma; Gastrointestinal Extranodal Lymphoma; Extranodal Lymphoma Involving the CNS and Spine; Genitourinary Extranodal Lymphoma; Musculoskeletal Extranodal Lymphoma; Pediatric Extranodal Lymphoma; Extranodal Lymphoma of the Breast; Cardiac Extranodal Lymphoma, and more!

This original fourteen chapter book is a brief, slightly autobiographic tale of medical oncologists, surgeons, radiation oncologists, and breast cancer patients in a well-established cancer center in Texas, who pursued the goal of cure for breast cancer. The evolution of improved outcomes in the treatment of microscopic metastatic breast cancer is also the story of the development of adjuvant chemotherapy for post-operative breast disease. The adjuvant therapy of breast cancer came about with the realization that this malignancy, when diagnosed in most patients, had spread beyond the confines of the primary cancer.
Patient histories in the form of Case Studies are used to illustrate certain issues. Devoted to the development of the chemotherapeutic regimens that currently are used to treat patients with advanced breast cancer.

This volume presents state-of-the-art information on each of the arms of the unfolded protein response (UPR), how their activation/repression are regulated, integrated, and coordinated, how UPR components affect cancer cell biology and responsiveness to therapeutic interventions, and how UPR components/activities offer potentially novel targets for drug discovery, repurposing, and development. The volume will provide the most recent information on the signaling and regulation of the UPR, explore examples of how the UPR and/or specific components contribute to cancer biology, and identify and explore specific examples of potently new actionable targets for drug discovery and development from within the UPR and its regulation. Unique to the volume will be a specific focus on the UPR and its role in cancer biology, as well as a discussion of the role of the UPR in drug responses and resistance in cancer.

Michael Sand gives the reader an overview of current techniques in expression profiling of miRNAs and their maturation machinery in the skin. This book is a postdoctoral thesis on miRNAs in cutaneous malignant melanoma and non-melanoma skin cancer with a focus on the miRNA processing machinery and miRNA expression profiling. The research presented in this book was performed in the Dermatologic Surgery Section at the Department of Dermatology, Venereology and Allergology of the Ruhr-University Bochum, Germany and gives the reader an overview of current techniques in expression profiling of miRNAs and their maturation machinery in the skin.

This book approaches the differential diagnosis and management of rare, hereditary cancer syndromes from a practical angle, addressing the issues pertinent to each tumour type as encountered by health professionals in their day-to-day practice. This book enables readers to correctly identify patients with rare cancer syndromes who would benefit from genetic counselling and testing, and provides the necessary knowledge for appropriate patient management and advising at-risk family members. It begins by describing recent advances in genetic testing for cancer-predisposing genes. Leading experts from Europe and Australia then offer detailed, up-to-date guidance on the diagnosis and management of a wide range of hereditary cancers. The concluding chapter examines the wider issues that are raised by genetic testing for rare cancer syndromes for patients, families and health professionals. This book is an invaluable source of information for all specialists involved in the care of such patients and their families.